These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38869865)

  • 1. Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Dong S; Wang Z; Zhang JT; Yan B; Zhang C; Gao X; Sun H; Li YS; Yan HH; Tu HY; Liu SM; Gong Y; Gao W; Huang J; Liao RQ; Lin JT; Ke EE; Xu Z; Zhang X; Xia X; Li AN; Liu SY; Pan Y; Yang JJ; Zhong WZ; Yi X; Zhou Q; Yang XN; Wu YL
    JAMA Oncol; 2024 Jul; 10(7):932-940. PubMed ID: 38869865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
    Hong MH; Choi YJ; Ahn HK; Lim SM; Keam B; Kim DW; Kim TM; Youk J; Kim YJ; Hwang S; Kim S; Kim JW; Kim HR; Kang JH
    JAMA Oncol; 2024 Oct; 10(10):1342-1351. PubMed ID: 39145962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
    Han JY; Ahn MJ; Lee KH; Lee YG; Kim DW; Min YJ; Kim SW; Cho EK; Kim JH; Lee GW; Lee SS; Lee NM; Jang HW; Han H; Park H; Lee J; Cho BC
    BMC Med; 2024 Oct; 22(1):428. PubMed ID: 39379931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
    Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
    Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
    Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3.
    Gray JE; Markovets A; Reungwetwattana T; Majem M; Nogami N; Peled N; Lee JS; Cho BC; Chewaskulyong B; John T; Han JY; Sebastian M; Todd A; Rukazenkov Y; Barrett C; Chmielecki J; Lee SM; Ramalingam SS; Hartmaier R
    J Thorac Oncol; 2024 Nov; 19(11):1525-1538. PubMed ID: 39029876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non-small-cell Lung Cancer Patients: The FOCUS-C Study.
    Zhang Y; Chen Z; Chen G; Huang Y; Yang Y; Fang W; Zhang L
    Clin Lung Cancer; 2024 Nov; 25(7):e357-e361.e17. PubMed ID: 38945800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.
    Xu J; Liu Z; Bai H; Dong G; Zhong J; Wan R; Zang A; Li X; Li Q; Guo J; Du N; Zhong D; Huang Y; Lv Q; Zhang J; Zhao Y; Gao L; Li L; Zhang C; Zhao J; Li B; Liu Z; Yang Z; Ji D; Wang T; Duan J; Wang Z; Wang J
    JAMA Oncol; 2022 Sep; 8(9):1328-1332. PubMed ID: 35862035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment.
    Acker F; Aguinarte L; Althoff F; Heinzen S; Rost M; Wild P; Reiser L; Mänz M; Meyer F; Stratmann J; Sebastian M
    Clin Lung Cancer; 2022 Nov; 23(7):e473-e477. PubMed ID: 36089483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.
    Zheng J; Wang Y; Hu C; Zhu M; Ii J; Lin C; Lu C; Dou Y; Zhao C; Zhang Y; Wu D; Li L; Tang H; He T; Pan C; Han R; He Y
    Thorac Cancer; 2022 Nov; 13(22):3162-3173. PubMed ID: 36193794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 13. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
    Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
    Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
    Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
    Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
    Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
    Provencio M; Ortega AL; Coves-Sarto J; Calvo V; Marsé-Fabregat R; Dómine M; Guirado M; Carcereny E; Fernández N; Álvarez R; Blanco R; León-Mateos L; Sánchez-Torres JM; Sullivan IG; Cobo M; Sánchez-Hernández A; Massuti B; Sierra-Rodero B; Mártinez-Toledo C; Serna-Blasco R; Romero A; Cruz-Bermúdez A
    JAMA Oncol; 2023 Mar; 9(3):344-353. PubMed ID: 36520426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
    O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
    Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.